Elevated carbohydrate antigen 125 post-operation as a prognostic marker in gastric cancer patients with stage II–III

Jingjing Li(Xuzhou Medical College), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Cong Luo(Central South University), Lei Chen(Zhuzhou Central Hospital), Qi Xu(Zhejiang Cancer Hospital)
Translational Cancer Research
September 1, 2020
10.21037/tcr-19-2427
Cited by 2

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412